Phaseline

Companies › Orca Biosystems

Orca Biosystems: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Orca-T
allogeneic stem cell and T-cell immunotherapy composed of purified hematopoietic stem and
–Phase 3Acute Myeloid Leukemia; Leukemia, Myeloid, AcuteApr 2027
OrcaGraft (Orca-Q)
engineered donor allograft for allogeneic hematopoietic cell transplantation
–Phase 1Acute Myeloid LeukemiaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05316701Orca-TPhase 3Acute Myeloid LeukemiaOncologyJul 2024
NCT06551584Orca-TPhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT04013685Orca-TPhase 1Acute Myeloid LeukemiaOncologyApr 2027
NCT07216443Orca-TPhase 2Leukemia, Myeloid, AcuteOncologyNov 2027
NCT03802695OrcaGraft (Orca-Q)Phase 1Acute Myeloid LeukemiaOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Binhui Biopharmaceutical 3D Medicines (Sichuan) PharmaEssentia Buzzard Pharmaceuticals Cellvax Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.